The Sodium-glucose Cotransporter 2 Inhibitor Tofogliflozin Prevents Diabetic Kidney Disease Progression in Type 2 Diabetic Mice

Overview

Journal FEBS Open Bio

Specialty Biology

Date 2020 Oct 24

PMID 33098615

Citations 9

Authors

Zi Li

Maki Murakoshi

Saki Ichikawa

Takeo Koshida

Eri Adachi

Chigure Suzuki

Seiji Ueda

Tomohito Gohda

Yusuke Suzuki

Affiliations

Soon will be listed here.

Abstract

Trials on cardiovascular and renal outcomes in patients with type 2 diabetes have consistently demonstrated that sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of diabetic kidney disease (DKD) progression. However, their renal protective mechanisms have yet to be completely understood and the effect on albuminuria reduction in animal models is controversial. We investigated these issues using KK and KK-A mice as a control (CTRL) and as a model for type 2 diabetes (DKD), respectively. KK-A mice were treated with 0.015% tofogliflozin, which is an SGLT2 inhibitor, starting at seven weeks of age for eight weeks. Compared with the CTRL mice, the DKD mice had higher HbA1c levels and albuminuria. Although tofogliflozin treatment significantly lowered HbA1c levels, it did not reverse albuminuria. Tofogliflozin treatment enhanced damage in both the glomerular (i.e., enlarged mesangial area, increased foot process effacement rate, and decreased number of WT-1-positive cells) and tubulointerstitial (increased protein levels of KIM-1 and MCP-1, increased number of macrophages, and abnormal mitochondrial morphology) areas. Our results suggest that tofogliflozin may prevent glomerular and tubulointerstitial damage, partly by ameliorating hyperglycemia, renal inflammation, and abnormal mitochondrial morphology.

Citing Articles

Upregulation of Piezo2 and increased extracellular matrix protein in diabetic kidney disease mice.

Oba R, Ueno H, Oishi A, Nagahama K, Kanzaki G, Tsuboi N Hypertens Res. 2025; .

PMID: 39833555 DOI: 10.1038/s41440-024-02082-y.

Longitudinal Trajectories of Biomarkers of Kidney Tubular Function in Type 1 Diabetes.

Limonte C, Gao X, Bebu I, Seegmiller J, Lorenzi G, Perkins B Kidney Int Rep. 2024; 9(5):1406-1418.

PMID: 38707816 PMC: 11068962. DOI: 10.1016/j.ekir.2023.11.030.

Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin.

Ito H, Inoue H, Izutsu T, Matsumoto S, Antoku S, Yamasaki T PLoS One. 2023; 18(9):e0292014.

PMID: 37733761 PMC: 10513294. DOI: 10.1371/journal.pone.0292014.

Optimizing diabetic kidney disease animal models: Insights from a meta-analytic approach.

Li F, Ma Z, Cai Y, Zhou J, Liu R Animal Model Exp Med. 2023; 6(5):433-451.

PMID: 37723622 PMC: 10614131. DOI: 10.1002/ame2.12350.

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus.

Nomura S, Shouzu A, Taniura T, Okuda Y, Omoto S, Suzuki M Clin Pharmacol. 2023; 15:41-55.

PMID: 37255963 PMC: 10226515. DOI: 10.2147/CPAA.S409786.

References

Takagi S, Li J, Takagaki Y, Kitada M, Nitta K, Takasu T . Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J Diabetes Investig. 2018; 9(5):1025-1032. PMC: 6123054. DOI: 10.1111/jdi.12802. View

Figueira M, Castiglione R, de Lemos Barbosa C, Ornellas F, da Silva Feltran G, Morales M . Diabetic rats present higher urinary loss of proteins and lower renal expression of megalin, cubilin, ClC-5, and CFTR. Physiol Rep. 2017; 5(13). PMC: 5506523. DOI: 10.14814/phy2.13335. View

Heerspink H, Perco P, Mulder S, Leierer J, Hansen M, Heinzel A . Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019; 62(7):1154-1166. PMC: 6560022. DOI: 10.1007/s00125-019-4859-4. View

Tanaka S, Sugiura Y, Saito H, Sugahara M, Higashijima Y, Yamaguchi J . Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. Kidney Int. 2018; 94(5):912-925. DOI: 10.1016/j.kint.2018.04.025. View

Takiyama Y, Sera T, Nakamura M, Ishizeki K, Saijo Y, Yanagimachi T . Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8. EBioMedicine. 2018; 36:329-346. PMC: 6197731. DOI: 10.1016/j.ebiom.2018.09.048. View

Brenner B, Cooper M, de Zeeuw D, Keane W, Mitch W, Parving H . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12):861-9. DOI: 10.1056/NEJMoa011161. View

Bryniarski M, Yee B, Jaffri I, Chaves L, Yu J, Guan X . Increased megalin expression in early type 2 diabetes: role of insulin-signaling pathways. Am J Physiol Renal Physiol. 2018; 315(5):F1191-F1207. DOI: 10.1152/ajprenal.00210.2018. View

Maldonado-Cervantes M, Galicia O, Moreno-Jaime B, Zapata-Morales J, Montoya-Contreras A, Bautista-Perez R . Autocrine modulation of glucose transporter SGLT2 by IL-6 and TNF-α in LLC-PK(1) cells. J Physiol Biochem. 2012; 68(3):411-20. DOI: 10.1007/s13105-012-0153-3. View

Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather A . Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One. 2014; 9(11):e108994. PMC: 4219667. DOI: 10.1371/journal.pone.0108994. View

10.

Persson P, Hansell P, Palm F . Tubular reabsorption and diabetes-induced glomerular hyperfiltration. Acta Physiol (Oxf). 2010; 200(1):3-10. PMC: 2919631. DOI: 10.1111/j.1748-1716.2010.02147.x. View

11.

Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R . SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care. 2016; 39 Suppl 2:S165-71. DOI: 10.2337/dcS15-3006. View

12.

Anderson R, Ternes S, Strand K, Rowling M . Vitamin D homeostasis is compromised due to increased urinary excretion of the 25-hydroxycholecalciferol-vitamin D-binding protein complex in the Zucker diabetic fatty rat. Am J Physiol Endocrinol Metab. 2010; 299(6):E959-67. DOI: 10.1152/ajpendo.00218.2010. View

13.

Bouhairie V, McGill J . Diabetic Kidney Disease. Mo Med. 2018; 113(5):390-394. PMC: 6139827. View

14.

Novikov A, Vallon V . Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens. 2015; 25(1):50-8. PMC: 4703043. DOI: 10.1097/MNH.0000000000000187. View

15.

Gohda T, Niewczas M, Ficociello L, Walker W, Skupien J, Rosetti F . Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012; 23(3):516-24. PMC: 3294299. DOI: 10.1681/ASN.2011060628. View

16.

Rabizadeh S, Nakhjavani M, Esteghamati A . Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. Int J Endocrinol Metab. 2019; 17(2):e84353. PMC: 6628616. DOI: 10.5812/ijem.84353. View

17.

Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S . Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. Horm Metab Res. 2015; 47(9):686-92. DOI: 10.1055/s-0034-1395609. View

18.

Umino H, Hasegawa K, Minakuchi H, Muraoka H, Kawaguchi T, Kanda T . High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection. Sci Rep. 2018; 8(1):6791. PMC: 5931531. DOI: 10.1038/s41598-018-25054-y. View

19.

Nakamura N, Matsui T, Ishibashi Y, Yamagishi S . Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation. Diabetol Metab Syndr. 2015; 7:48. PMC: 4447012. DOI: 10.1186/s13098-015-0044-1. View

20.

Gallo L, Ward M, Fotheringham A, Zhuang A, Borg D, Flemming N . Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep. 2016; 6:26428. PMC: 4881020. DOI: 10.1038/srep26428. View